HCV Trial Begins for New Immune Drug | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Medivir AB and Tibotec Partner Up To Develop Hepatitis C Polymerase Drug

Back to News Homepage
Next

Hepatitis, Liver Enzymes and Fibrosis Progression

HCV Trial Begins for New Immune Drug

The Editors at Hepatitis Central
October 23, 2009

Print this page

SciClone begins a Phase II trial to evaluate how a new drug designed to stimulate the immune system fares against Hepatitis C.

SciClone starts hepatitis C drug trial

Wednesday, October 21, 2009

SciClone Pharmaceuticals Inc. enrolled the first patient in a mid-stage test of a hepatitis C treatment.

Foster City-based SciClone (NASDAQ: SCLN) signed up the patient in Atlanta to test SCV-07, a small molecule that stimulates the immune system. In this Phase II trial it’s being tested alone or in combination with ribavirin, another drug.

Read the entire article:
http://sanfrancisco.bizjournals.com/sanfrancisco/stories/2009/10/19/daily47.html

No Comments - be the first!
Share
Share
Previous

Medivir AB and Tibotec Partner Up To Develop Hepatitis C Polymerase Drug

Back to News Homepage
Next

Hepatitis, Liver Enzymes and Fibrosis Progression

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.